Abstract
Adipose tissue is the largest endocrine gland in the body, yet only recently has its role in neurodegenerative disease been considered. Prospective population level evidence has emerged to show that both obesity and overweight, is associated with an increased risk of all cause dementia, Alzheimers disease (AD), and underlying neurodegenerative changes. Weight loss in late life however is associated with dementia, and those categorized as underweight are also at a greater risk of dementia. Given the current epidemic of obesity, and the expected age-related increase in dementia incidence, even a small association between these two diseases has far reaching public health implications. However, due to the effects of both AD-associated weight loss and age-related changes in body composition, there are methodological challenges in appropriately evaluating obesity as a risk factor for developing dementia. There is a need to take a ‘life course approach’ and to consider the role of risk factors prior to the onset of old age. Our work has shown that both obesity and overweight, as measured by body mass index and skinfold thickness, in middle-age are strongly associated with an increased risk of all cause dementia, Alzheimer disease & Vascular dementia, independent of the development of diabetes and cardiovascular-related morbidities. There is also value in assessing regional body shape distributions of adiposity, particular the role of abdominal obesity. Mechanistic pathways such as adipocyte secreted proteins and hormones, and inflammatory cytokines could explain the association between obesity and increased risk of dementia.
Keywords: Obesity, Alzheimer disease, body mass index, adiposity, dementia, leptin, adioponectin, abdominal obesity
Current Alzheimer Research
Title: The Epidemiology of Adiposity and Dementia
Volume: 4 Issue: 2
Author(s): Rachel A. Whitmer
Affiliation:
Keywords: Obesity, Alzheimer disease, body mass index, adiposity, dementia, leptin, adioponectin, abdominal obesity
Abstract: Adipose tissue is the largest endocrine gland in the body, yet only recently has its role in neurodegenerative disease been considered. Prospective population level evidence has emerged to show that both obesity and overweight, is associated with an increased risk of all cause dementia, Alzheimers disease (AD), and underlying neurodegenerative changes. Weight loss in late life however is associated with dementia, and those categorized as underweight are also at a greater risk of dementia. Given the current epidemic of obesity, and the expected age-related increase in dementia incidence, even a small association between these two diseases has far reaching public health implications. However, due to the effects of both AD-associated weight loss and age-related changes in body composition, there are methodological challenges in appropriately evaluating obesity as a risk factor for developing dementia. There is a need to take a ‘life course approach’ and to consider the role of risk factors prior to the onset of old age. Our work has shown that both obesity and overweight, as measured by body mass index and skinfold thickness, in middle-age are strongly associated with an increased risk of all cause dementia, Alzheimer disease & Vascular dementia, independent of the development of diabetes and cardiovascular-related morbidities. There is also value in assessing regional body shape distributions of adiposity, particular the role of abdominal obesity. Mechanistic pathways such as adipocyte secreted proteins and hormones, and inflammatory cytokines could explain the association between obesity and increased risk of dementia.
Export Options
About this article
Cite this article as:
Whitmer A. Rachel, The Epidemiology of Adiposity and Dementia, Current Alzheimer Research 2007; 4 (2) . https://dx.doi.org/10.2174/156720507780362065
DOI https://dx.doi.org/10.2174/156720507780362065 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
Early nutritional intervention and physical activity in the prevention of Alzheimer's disease and other dementias
The aim is to broaden the knowledge about the impact of the consumption of food ingredients, diet ingredients, methods of processing of food raw materials as well as the impact of composing of diets on the possibility of preventing Alzheimer's disease and other types of dementia at each stage of ...read more
Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging
The thematic issue, Enhancing Alzheimer's Disease Diagnosis and Treatment Efficacy Prediction with Explainable AI, Radiomics, Biomarkers, and Multimodal Neuroimaging, aims to bridge the gap between advanced computational techniques and clinical practice in Alzheimer’s disease research. Alzheimer’s disease poses significant challenges in early diagnosis, disease progression monitoring, and predicting treatment efficacy. ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Occupational Complexity and Leisure Activities in Cognitive Aging
Current Psychopharmacology Automatic Assessment of Cognitive Tests for Differentiating Mild Cognitive Impairment: A Proof of Concept Study of the Digit Span Task
Current Alzheimer Research Meet Our Editorial Board Member
Current Alzheimer Research The Protective Effects of Natural Products on Blood-Brain Barrier Breakdown
Current Medicinal Chemistry When Sick Brain and Hopelessness Meet: Some Aspects of Suicidality in the Neurological Patient
CNS & Neurological Disorders - Drug Targets Bevacizumab in Non Small Cell Lung Cancer: Development, Current Status and Issues
Current Medicinal Chemistry Pleiotropic Effects of Cathepsin D
Endocrine, Metabolic & Immune Disorders - Drug Targets Pharmacology and Therapeutics of Gabapentin in the Treatment of Psychiatric Disorders; Present and Future Perspectives
Current Neuropharmacology Proteomics Approaches to Understand Linkage Between Alzheimer’s Disease and Type 2 Diabetes Mellitus
CNS & Neurological Disorders - Drug Targets Bromelain Degrades Aβ1-42 Monomers and Soluble Aggregates: An In Vitro Study in Cerebrospinal Fluid of Alzheimer’s Disease Patients
Current Alzheimer Research The Safety, Tolerability, Pharmacokinetics and Cognitive Effects of GSK239512, a Selective Histamine H<sub>3</sub> Receptor Antagonist in Patients with Mild to Moderate Alzheimer’s Disease: A Preliminary Investigation
Current Alzheimer Research Treatments for Hypertension in Type 2 Diabetes-Non-pharmacological and Pharmacological Measurements<sup>#</sup>
Current Hypertension Reviews Therapeutic Strategies Targeting Amyloid-β in Alzheimer’s Disease
Current Alzheimer Research Neuroimaging Findings Related to Behavioral Disturbances in Alzheimer's Disease: A Systematic Review
Current Alzheimer Research Involvement of Rat Hippocampal Astrocytes in β-Amyloid-Induced Angiogenesis and Neuroinflammation
Current Alzheimer Research Modeling Parkinson’s Disease in Zebrafish
CNS & Neurological Disorders - Drug Targets Advanced Nanomedicines for the Treatment and Diagnosis of Myocardial Infarction and Heart Failure
Current Drug Targets Spatio-Temporal Fluctuations of Neural Dynamics in Mild Cognitive Impairment and Alzheimer’s Disease
Current Alzheimer Research Recent Studies on Design and Development of Drugs Against Alzheimer’s Disease (AD) Based on Inhibition of BACE-1 and Other AD-causative Agents
Current Topics in Medicinal Chemistry Obesity and Metabolic Syndrome Affect the Cholinergic Transmission a nd Cognitive Functions
CNS & Neurological Disorders - Drug Targets